The debate on XL184—i.e. whether BMY screwed up by ditching it—cannot be settled today. All told, I’m less inclined than some posters on this board to assume that XL184 must be a great drug just because EXEL is “all in.” Such a notion could be added to microcapfun’s list of common newbie mistakes in #msg-64797776.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.